Autotransplant conditioning regimens for aggressive lymphoma:: are we on the right road?

被引:32
作者
Fernandez, H. F.
Escalon, M. P.
Pereira, D.
Lazarus, H. M.
机构
[1] Univ S Florida, Div Blood & Marrow Transplant, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Div Hematol Oncol, Dept Med, Miami, FL 33152 USA
[3] Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA
关键词
autologous stem cell transplant; lymphoma; purging; conditioning regimens;
D O I
10.1038/sj.bmt.1705744
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
High-dose chemotherapy and autologous stem cell transplant (ASCT) is the standard approach for chemosensitive, relapsed aggressive non-Hodgkin's lymphoma (NHL). Various conditioning regimens have been used as treatment before ASCT and disease-free (DFS) and overall survival (OS) rates range from 34 to 60% and 26 to 46%, respectively. To date, few comparative randomized trials have been performed and no regimen has demonstrated superiority to another. Reduction of disease relapse remains the major hurdle for improving patient outcome and in vitro and in vivo purging of lymphoma cells has not necessarily enhanced results. Rituximab pre-mobilization and post-transplant appear to provide better response rates with OS approaching 87-91% at 2-3 years. Newer approaches with radioimmunotherapy may raise DFS to 78% and OS to 93%, albeit with short follow-up. Advances in the conditioning regimens and supportive care have reduced transplant- related mortality to less than 10%. In this review we discuss commonly utilized conditioning regimens, describe their pros and cons and address purging and present conditioning strategies. Owing to the poor outcome with conventional chemotherapy in mantle cell, Burkitt's and T-cell lymphoma, we propose the standard approach of frontline ASCT for these high-risk lymphoma patients. Finally, we will present novel strategies, which can enhance the anti-lymphoma effect, at the same time reducing toxicity, to improve the outcome of ASCT in NHL patients.
引用
收藏
页码:505 / 513
页数:9
相关论文
共 65 条
[1]   A phase II, multicenter, randomized, double-blind, placebo-controlled trial of the safety and efficacy of velafermin (CG53135-05) administered intravenously as a single dose for the prevention of oral mucositis in patients receiving autologous hematopoietic stem cell transplant (AHSCT) [J].
Anaissie, E ;
Schuster, MW ;
Hurd, D ;
Bensinger, W ;
Mason, J ;
McCarty, JM ;
Rifkin, R ;
Maziarz, R ;
Bolwell, B ;
Mehta, J ;
Mangan, K ;
Skikne, B ;
Abboud, C ;
Chao, N ;
Stadtmauer, E ;
Fernandez, H ;
Lazarus, H ;
Westervelt, P ;
Halvorsen, Y ;
Gerwien, R ;
Annino, V ;
Habne, W .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) :21-22
[2]  
Blay JY, 1998, BLOOD, V92, P3562
[3]   High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas [J].
Blystad, AK ;
Enblad, G ;
Kvaloy, S ;
Berglund, Å ;
Delabie, J ;
Holte, H ;
Carlson, K ;
Kvalheim, G ;
Bengtsson, M ;
Hagberg, H .
BONE MARROW TRANSPLANTATION, 2001, 27 (07) :711-716
[4]   High-dose therapy supported with immunomagnetic purged autologous bone marrow in high-grade B cell non-Hodgkin's lymphoma [J].
Blystad, AK ;
Kvalheim, G ;
Torlakovic, E ;
Holte, H ;
Jacobsen, E ;
Beiske, K ;
Vålerhaugen, H ;
Lenschow, E ;
Kvaloy, S .
BONE MARROW TRANSPLANTATION, 1999, 24 (08) :865-872
[5]   BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors [J].
Caballero, MD ;
Rubio, V ;
Rifon, J ;
Heras, I ;
GarciaSanz, R ;
Vazquez, L ;
Vidriales, B ;
delCanizo, MC ;
Corrall, M ;
Gonzalez, M ;
Leon, A ;
JeanPaul, E ;
Rocha, E ;
Moraleda, JM ;
SanMiguel, JF .
BONE MARROW TRANSPLANTATION, 1997, 20 (06) :451-458
[6]  
Cilley Jeffrey, 2006, Haematologica, V91, P114
[7]   Rituximab-dependent cytotoxicity by natural killer cells:: Influence of FCGR3A polymorphism on the concentration-effect relationship [J].
Dall'Ozzo, S ;
Tartas, S ;
Paintaud, G ;
Cartron, G ;
Colombat, P ;
Bardos, P ;
Watier, H ;
Thibault, G .
CANCER RESEARCH, 2004, 64 (13) :4664-4669
[8]   Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma [J].
deMagalhaesSilverman, M ;
Lister, J ;
Rybka, W ;
Wilson, J ;
Ball, E .
BONE MARROW TRANSPLANTATION, 1997, 19 (08) :777-781
[9]  
DOUGLAS S, 2006, ASH ANN M ABSTR, V108, P3383
[10]  
FERNANDEZ HF, 2006, ASBMTICIBMTR TAND M